Anti-idiotypic antibody abagovomab in advanced ovarian cancer

Ovarian cancer is the fifth most common malignancy with approximately 22,000 newly diagnosed cases each year in the USA. Standard of care after cytoreductive surgery is the application of carboplatin and paclitaxel. The newly developed anti-idiotypic monoclonal antibody abagovomab demonstrated promi...

Full description

Saved in:

Bibliographic Details
Published in:	Future oncology (London, England) Vol. 4; no. 6; p. 769
Main Authors:	Bauerschlag, Dirk O, Schem, Christian, Baumann, Klaus, Harter, Philip, Hilpert, Felix, Wagner, Uwe, du Bois, Andreas, Pfisterer, Jakobus
Format:	Journal Article
Language:	English
Published:	England 01-12-2008
Subjects:	Antibodies, Anti-Idiotypic - therapeutic use Antibodies, Monoclonal Antineoplastic Agents - therapeutic use Clinical Trials as Topic Female Humans Ovarian Neoplasms - drug therapy
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Ovarian cancer is the fifth most common malignancy with approximately 22,000 newly diagnosed cases each year in the USA. Standard of care after cytoreductive surgery is the application of carboplatin and paclitaxel. The newly developed anti-idiotypic monoclonal antibody abagovomab demonstrated promising results in Phase I/II trials. This new type of drug is currently being tested in a Phase II/III trial in ovarian cancer patients with a complete response after standard first-line chemotherapy. Activating the cancer hosts immune system is a new strategy that is worth being pursued in the fight against ovarian cancer.
ISSN:	1744-8301
DOI:	10.2217/14796694.4.6.769